Cornelia Quadt

3.8k citations

53 papers · 2.2k indexed · 1 hit paper · h-index 25

Impact in

Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways

Papers in ⓘ

Genetics 13
- Chronic Lymphocytic Leukemia Research 11
Oncology 21
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 4
- Colorectal Cancer Treatments and Studies 3

Co-authors: Dejan Juric (14 shared papers)Michael Rugaard Jensen (10 shared papers)Jordi Rodón (12 shared papers)José Baselga (12 shared papers)Douglas Bootle (10 shared papers)Howard A. Burris (10 shared papers)David Demanse (14 shared papers)Mark R. Middleton (6 shared papers)
Journals: Cancer Research (13 papers)Journal of Clinical Oncology (9 papers)Molecular Cancer Therapeutics (4 papers)Blood (4 papers)Annals of Oncology (3 papers)
Partner nations: Switzerland United States Spain

In The Last Decade

Cornelia Quadt

52 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study 2018 · 302 citations

Peers

Countries citing papers authored by Cornelia Quadt

Since Specialization

Citations

This map shows the geographic impact of Cornelia Quadt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cornelia Quadt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cornelia Quadt more than expected).

Fields of papers citing papers by Cornelia Quadt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cornelia Quadt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cornelia Quadt. The network helps show where Cornelia Quadt may publish in the future.

Co-authors

The 25 scholars most cited alongside Cornelia Quadt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Cornelia Quadt Line = papers co-authored together Cornelia Quadt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga Hit paper breakdown →	2018	302
2	PI3K inhibitors as new cancer therapeutics: implications for clinical trial design OncoTargets and Therapy ·Cristian Massacesi, Emmanuelle di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath, Samit Hirawat	2016	195
3	NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Breast Cancer Research ·Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski, Andrew J. Massey, Chantale T. Guy, Josef Brueggen, Cornelia Quadt, Alan Buckler, Robert Cozens, Martin J. Drysdale, Carlos Garcı́a-Echeverrı́a, Patrick Chêne	2008	189
4	Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer JAMA Oncology ·Dejan Juric, Filip Jankú, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiss‐Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo	2018	186
5	First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, Karen S. Jacks, Monica Mita, Vali Papadimitrakopoulou, Tim Pluard, Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, Cristina Fernandez‐Ibarra, Hong Lü, Stuart Bailey, Sandra Chica, Udai Banerji	2013	119
6	⁸⁹Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922 Journal of Nuclear Medicine ·Wouter B. Nagengast, Maarten A. de Korte, Thijs H. Oude Munnink, Hetty Timmer‐Bosscha, Wilfred F.A. den Dunnen, Harry Hollema, Johan R. de Jong, Michael Rugaard Jensen, Cornelia Quadt, Carlos Garcı́a-Echeverrı́a, Guus A.M.S. van Dongen, Marjolijn N. Lub–de Hooge, Carolien P. Schröder, Elisabeth G.E. de Vries	2010	96
7	89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft European Journal of Cancer ·Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast, Hetty Timmer‐Bosscha, Carolina P. Schröder, Johan R. de Jong, Guus A.M.S. van Dongen, Michael Rugaard Jensen, Cornelia Quadt, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries	2009	80
8	T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Cancer Immunology Immunotherapy ·Bernd Schlereth, Cornelia Quadt, Torsten Dreier, Peter Kufer, Grit Lorenczewski, Nadja Prang, Christian Brandl, Sandra Lippold, KATHY E. COBB, Kathleen M. Brasky, Eugen Leo, Ralf C. Bargou, Krishna K. Murthy, Patrick A. Baeuerle	2005	77
9	Phase I dose‐escalation study of buparlisib (BKM120), an oral pan‐class I PI3K inhibitor, in Japanese patients with advanced solid tumors Cancer Science ·Yukio Ando, Megumi Inada‐Inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi	2014	73
10	Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma Leukemia ·Thorsten Stühmer, Angela Zöllinger, Daniela Siegmund, Manik Chatterjee, Evelyn Grella, Stefan Knop, K. Martin Kortüm, Christian Unzicker, Michael Rugaard Jensen, Cornelia Quadt, Patrick Chêne, Joseph Schoepfer, Carlos Garcı́a-Echeverrı́a, Hermann Einsele, Harald Wajant, Ralf C. Bargou	2008	67
11	Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer Molecular Cancer Therapeutics ·Zev A. Wainberg, Adrian Anghel, Amy M. Rogers, Amrita Desai, Ondrej Kalous, Dylan Conklin, Raul Ayala, Neil A. O’Brien, Cornelia Quadt, Mikhail Akimov, Dennis J. Slamon, Richard S. Finn	2013	58
12	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth Molecular Cancer Therapeutics ·Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita Desai, Wylie Hosmer, Susan Ide, Emin Avşar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon	2013	56
13	Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Cancer Research ·Dejan Juric, Jordi Rodón, Ana M. González-Angulo, Howard A. Burris, Johanna C. Bendell, Jordan Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, José Baselga	2012	48
14	Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. Journal of Clinical Oncology ·Ana M. González-Angulo, Dejan Juric, Guillem Argilés, Jan H.M. Schellens, Howard A. Burris, Jordan Berlin, Mark R. Middleton, Martin Schüler, Robin M.J.M. van Geel, Thorunn Helgason, Douglas Bootle, Markus Boehm, Timothy Goggin, David Demanse, Cornelia Quadt, José Baselga	2013	43
15	Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors Cancer Science ·Yuichi Ando, Satoru Iwasa, Shunji Takahashi, Hideo Saka, Tomoyuki Kakizume, Kazuto Natsume, Naoko Suenaga, Cornelia Quadt, Yasuhide Yamada	2018	41
16	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer Cancer Chemotherapy and Pharmacology ·Jordi Rodón, José Alejandro Pérez Fidalgo, Ian E. Krop, Howard A. Burris, Ángel Guerrero‐Zotano, Carolyn D. Britten, Carlos Becerra, Jan H.M. Schellens, Donald Richards, Martin Schüler, Maysa Abu‐Khalaf, Faye M. Johnson, Malcolm Ranson, Jeff Edenfield, Antonio P. Silva, Wolfgang Hackl, Cornelia Quadt, David Demanse, Vincent Duval, José Baselga	2018	40
17	A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. Journal of Clinical Oncology ·James D. Peyton, Jordi Rodón, H. Burris, Carolyn D. Britten, L. C. Chen, Josep Tabernero, Vincent Duval, Nicolas Rouyrre, A. P. Silva, Cornelia Quadt, José Baselga	2011	39
18	A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients European Journal of Cancer ·Ralf Oberneder, Dorothea Weckermann, Beatrice Ebner, Cornelia Quadt, Petra Kirchinger, Tobias Raum, Mathias Locher, Nadja Prang, Patrick A. Baeuerle, Eugen Leo	2006	38
19	Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma European Journal Of Haematology ·Martin Kaiser, Britta Lamottke, Maren Mieth, Michael Rugaard Jensen, Cornelia Quadt, Carlos Garcı́a-Echeverrı́a, Peter Atadja, Ulrike Heider, Ivana von Metzler, Seval Türkmen, Orhan Sezer	2009	36
20	AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies. Journal of Clinical Oncology ·Thomas A. Samuel, Cristiana Sessa, Carolyn D. Britten, Karen Milligan, Monica Mita, Udai Banerji, TJ Pluard, Philipp Stiegler, Cornelia Quadt, Geoffrey I. Shapiro	2010	34

About Cornelia Quadt

Cornelia Quadt is a scholar working on Genetics, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Immunology, having authored 53 papers that have together received 2.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (21 papers), Advanced Breast Cancer Therapies (17 papers), Cancer Treatment and Pharmacology (14 papers), Heat shock proteins research (12 papers), Chronic Lymphocytic Leukemia Research (11 papers), ATP Synthase and ATPases Research (6 papers), HER2/EGFR in Cancer Research (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Genetics (301 citations), Oncology (756 citations), Molecular Biology (1.4k citations), Cancer Research (273 citations) and Pulmonary and Respiratory Medicine (591 citations). Cornelia Quadt has collaborated with scholars based in Switzerland, United States and Spain. Frequent co-authors include Dejan Juric, Michael Rugaard Jensen, Jordi Rodón, José Baselga, Douglas Bootle, Howard A. Burris, David Demanse, Mark R. Middleton, Martin Schüler and Carlos Garcı́a-Echeverrı́a. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Molecular Cancer Therapeutics, Blood and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact